Option Care Health, Inc. (OPCH) fair value analysis
Nasdaq · Updated 2026-10-19
OPCH price how computed
Forward Fair Value verdict
UndervaluedOPCH is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $31.20
- Sector
- Healthcare
- 12-month range
- $19.52–$36.59
- Market cap
- $4.67B
- From 52-week high
- -14.7%
- Shares outstanding
- 150M
- Rank in Healthcare by discount to fair value
- #15 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Option Care Health, Inc. is a healthcare company that provides infusion and ancillary services to patients in home and alternate care settings. The company operates across the United States, delivering medications and therapies to patients outside of traditional hospital environments.
OPCH currently ranks #15 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $4.67B
- P/E (trailing)
- 18x
- Revenue (TTM)
- $5.69B
- Net margin
- 3.7%
- EPS (TTM)
- $1.72
- Gross margin
- 18.5%
- Debt / equity
- 1.01
- Revenue growth (3-yr avg)
- 10.7%
- Shares outstanding
- 150M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 80 · overbought
- 50-day average
- $24.99
- 200-day average
- $26.39
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+10.8%)
2026-03 ▲ beat (+8.1%)
2025-12 ▼ miss (-1.2%)
2025-09 ▲ beat (+4.7%)
2025-06 ▲ beat (+2.5%)
2025-03 ▲ beat (+17.6%)
2024-12 ▲ beat (+2.0%)
2024-09 ▲ beat (+3.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 5 hold · 0 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $30
- Target vs last price
- -3.8%
What our data shows for OPCH
- Our model validated 17 trailing price-to-earnings windows for OPCH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $19.52–$36.59.
- The 14-day relative strength index sits at an overbought 80.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for OPCH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent OPCH news
TickrTrends' derived news-sentiment signal for OPCH is currently leaning positive, computed from recent coverage.
- McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified? (insidermonkey.com, 2026-10-09)
TickrTrends take: McKesson's acquisition of Option Care Health represents a significant consolidation move in the healthcare distribution and services sector. Given TickrTrends' current undervalued assessment of OPCH, investors focused on valuation metrics should monitor whether the acquisition price validates or challenges that undervalued status, particularly by examining what multiples McKesson is paying relative to OPCH's earnings and cash flow. The deal's strategic rationale and integration synergies will be key factors in determining whether current market pricing reflects the true value of OPCH's assets and market position within the broader healthcare sector. - Option Care: Booking My Gains Ahead Of Deal Completion (NASDAQ:OPCH) (seekingalpha.com, 2026-10-07)
TickrTrends take: Option Care Health operates in the Healthcare sector and is currently assessed as undervalued according to TickrTrends valuation metrics. The pending deal completion presents a timing consideration for investors tracking the company's valuation, as transaction-related developments can affect how traditional valuation measures apply during transition periods. Valuation-focused observers should monitor whether the deal's progression influences the gap between OPCH's current market price and its fundamental valuation indicators. - US stocks: S&P 500, Nasdaq reach record closing highs as focus pivots to earnings (economictimes.indiatimes.com, 2026-10-06)
TickrTrends take: OPCH operates in the Healthcare sector, which is part of the broader US equity market that recently achieved record closing highs in major indices. With TickrTrends currently assessing OPCH as undervalued, investors focused on valuation metrics should monitor whether the company's earnings reports demonstrate fundamental strength that justifies such a designation amid the current market environment. As market focus pivots toward earnings season, OPCH's ability to deliver results relative to its peers in Healthcare will be a key factor in validating whether its current undervalued status reflects a genuine opportunity or simply reflects market sentiment.
What people are saying
Follow the OPCH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for OPCH show mixed movement this week despite the stock remaining in the Healthcare sector. The DCF cross-check band shifted from undervalued to fairly valued, while the 50/200-day trend state moved from downtrend to mixed, suggesting some stabilization in price momentum. The RSI zone moved into overbought territory from neutral, and the sector discount rank declined from number 7 to number 22, indicating the stock is now less attractively valued relative to its Healthcare peers.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for OPCH showed a shift this week as the 50/200-day trend state moved from mixed to downtrend. Despite this technical deterioration, the current valuation verdict remains undervalued. The downtrend development represents a change in the stock's intermediate momentum trajectory compared to the prior week's assessment.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is OPCH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), OPCH is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is OPCH's TickrTrends verdict?
OPCH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does OPCH compare to other Healthcare stocks?
OPCH ranks #15 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is OPCH overbought or oversold?
OPCH's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
When does OPCH report earnings next?
OPCH's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does OPCH usually beat earnings estimates?
Over its last 8 reported quarters OPCH beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about OPCH?
Of 13 analysts covering OPCH, 8 rate it a buy, 5 a hold and 0 a sell - buy-leaning, with a consensus price target of $30 (-3.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
OPCH vs DXCM · OPCH vs EMBC · OPCH vs HQY · OPCH vs INDV · OPCH vs LMAT